Latest from biontech
In November, Gulf states Bahrain and Saudi Arabia approved the Pfizer Covid-19 vaccine for emergency use for children in the same age category.
A study, conducted by scientists at the microbiology department of the University of Hong Kong, showed that insufficient antibodies were generated by the Sinovac and BioNTech products to fend off Omicron.
Written by Joydeep Bose | Edited by Avik Roy, Hindustan Times, New Delhi
Further, the companies also said that two doses of the vaccine was found less effective in protection against the Omicron variant while a booster dose increased the neutralising antibodies by 25 times.
Written by Srivatsan K C | Edited by Avik Roy, Hindustan Times, New Delhi
- BioNTech, which works with Pfizer said it’s beginning lab studies on the variant and should have the first data on how it interacts with the vaccine within two weeks.
- As Europe begins to open up, DW offers a brief recap of what travel restrictions apply within the EU.